Index
Module 6 • Infectious Diseases
Infectious Diseases I
2%
🦠
Infectious Diseases I
Module 6 • 61 pages
Progress
2% • 1/61
1
Infectious Diseases I Jacob Schwarz, Pharm.D., MBA
2
Infectious Diseases I Infectious Diseases I Jacob
3
Infectious Diseases I Learning Objectives 1. Deve
4
Infectious Diseases I 2. Based on the 2016 IDSA g
5
Infectious Diseases I 8. J.E. is a 67-year-old wo
6
Infectious Diseases I BPS Critical Care Pharmacy E
7
Infectious Diseases I I. VENTILATOR-ASSOCIATED PN
8
Infectious Diseases I i. Preferentially use multi
9
Infectious Diseases I a. If an invasive strategy
10
Infectious Diseases I Table 1. VAP Classifications
11
Infectious Diseases I 4. Definitive antibiotic th
12
Infectious Diseases I (c) The rate of MDR pathoge
13
Infectious Diseases I Characteristic 2005 Guidelin
14
Infectious Diseases I Patient Cases 1. C.T. is a
15
Infectious Diseases I B. Diagnosis 1. Clinical s
16
Infectious Diseases I b. Complicated CLABSI i. E
17
Infectious Diseases I Patient Cases (continued) Qu
18
Infectious Diseases I C. Treatment 1. A urinary
19
Infectious Diseases I IV. COMPLICATED INTRA-ABDOM
20
Infectious Diseases I a. Esophageal, gastric, and
21
Infectious Diseases I c. Community-acquired, mild
22
Infectious Diseases I iii. Anti-enterococcal ther
23
Infectious Diseases I Patient Cases 9. D.L. is a
24
Infectious Diseases I 2. About 20% –30% of acute
25
Infectious Diseases I 5. Additional late complica
26
Infectious Diseases I v. If infection is confirme
27
Infectious Diseases I 2. C. difficile is transmit
28
Infectious Diseases I C. Risk Factors 1. Antibio
29
Infectious Diseases I c. Enzyme immunoassay (EIA)
30
Infectious Diseases I iii. Metronidazole is prima
31
Infectious Diseases I Table 3. Treatment Options f
32
Infectious Diseases I Clinical Definition ACG 201
33
Infectious Diseases I Clinical Definition ACG 201
34
Infectious Diseases I Patient Cases 14. K.L. is a
35
Infectious Diseases I VII. WOUND INFECTION A. Th
36
Infectious Diseases I b. Antibiotic therapy is em
37
Infectious Diseases I VIII. INFLUENZA A. Epidemi
38
Infectious Diseases I 3. Institutions should begi
39
Infectious Diseases I c. Neuraminidase inhibitors
40
Infectious Diseases I ii. High levels of resistan
41
Infectious Diseases I Agent Influenza Activity Bi
42
Infectious Diseases I Patient Cases 19. T.Y., a 3
43
Infectious Diseases I 6. Risk factors for COVID-1
44
Infectious Diseases I 4. The incubation period fo
45
Infectious Diseases I ii. Fluid resuscitation: Co
46
Infectious Diseases I (1) The COVACTA trial (N En
47
Infectious Diseases I (A) At enrollment, 32% of p
48
Infectious Diseases I (3) Anti–IL-6 monoclonal an
49
Infectious Diseases I ii. Hydroxychloroquine or c
50
Infectious Diseases I Disease Severity Remdesivi
51
Infectious Diseases I REFERENCES Ventilator-Associ
52
Infectious Diseases I infections in the ICU. N Eng
53
Infectious Diseases I Dellinger EP, Tellado JM, So
54
Infectious Diseases I Wound Infection Anaya DA, De
55
Infectious Diseases I Kalil AC, Patterson TF, Meht
56
Infectious Diseases I ANSWERS AND EXPLANATIONS TO
57
Infectious Diseases I antibiotic therapy should be
58
Infectious Diseases I gram-negative bacilli and ye
59
Infectious Diseases I 19. Answer: D This patient
60
Infectious Diseases I ANSWERS AND EXPLANATIONS TO
61
Infectious Diseases I and guideline recommendation
Core Content
Infectious Diseases I
Jacob Schwarz
~1 min read
Module 6 of 20
1
/ 61
Infectious Diseases I
Jacob Schwarz, Pharm.D., MBA, FAzPA, BCIDP,
BCCCP, BCPS
Mayo Clinic
Phoenix, AZ
HD Video Explanation — Synchronized with PDF
Starts at: minute 0
Open on YouTube
Module Index
Page
/ 61
←
→
navigate
Space
next
Next